Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Several key developments in the health sector involve major pharmaceutical companies navigating growth challenges and ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

A woman's hands star in a Lilly spot, shown playing key role in activities like gardening -- and discovering a lump in her ...

Ore Huiying / Bloomberg / Getty Images Eli Lilly shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year. The maker of weight-loss drugs Mounjaro and ...

Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy ... Zacks Investment Research Image Source: Zacks Investment Research Pivoting to Novo Nordisk, its top line is projected to expand 18% in ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. This decline includes a sell-off earlier this week after Lilly cut its 2024 revenue guidance due to lower-than-expected ...

Pfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its ...

Eli Lilly's operational performance is strong ... As an example, we need only look at the image below. This shows the company's current pipeline of drugs that are in either Phase 1, Phase 2 ...